Accelerating ADCs’ development pipeline using Simcyp PBPK

With nearly 10 million deaths in 2020 and despite great progress, cancer remains the leading cause of death worldwide [1]. Antibody Drug Conjugates (ADCs) when first approved in 2000, seemed ideal in that they could deliver the cytotoxic drug (also referred to as the warhead) directly to the tumor site, resulting in reduced off-target damage … Continued

A Day in the Life of a Clinical Pharmacology Consultant

Strategic consulting within drug discovery and development is an exciting career choice for many. Unlike a biotechnology or pharmaceutical enterprise, where the assets one typically works on are within that ecosystem, consulting offers the possibility of working on many different innovation pipelines. At any given time, you might be working on solving a problem for … Continued

Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam

Risdiplam (EVRYSDI) is approved for the treatment of patients with spinal muscular atrophy ≥ 2 months old. CYP3A-mediated DDI risk in pediatric patients was evaluated by physiologically-based pharmacokinetic (PBPK) modelling and informed the label. This talk will illustrate a modeling strategy for the extrapolation of DDIs from adults to children covering: Development of a patient-specific … Continued

1 of 25
Back to top
Powered by Translations.com GlobalLink OneLink Software